Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: Recurrent Urinary Tract Infection, Hypoestrogenism
Interventions: Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Trichomonas Vaginalis
Interventions: APTIMA Trichomonas vaginalis (ATV) Assay; Device
Lead sponsor: Gen-Probe, Incorporated; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 4 more

Conditions: Dyspareunia, Pelvic Pain, Sexual Dysfunction, Radiation Toxicity
Interventions: Pelvic health therapy, Dilator feasability; Behavioral · Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana

Conditions: Chlamydia Infections, Gonorrhea
Interventions: APTIMA Assays; PANTHER System; Device
Lead sponsor: Gen-Probe, Incorporated; Industry
Eligibility: 16 Years and older
Enrollment: 1,492 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more

Conditions: Anesthesia, Local, Prolapse, Prolapse; Female, Prolapse, Vaginal, Prolapse; Vagina, Posthysterectomy, Pain, Postoperative
Interventions: TAP block; Procedure
Lead sponsor: ProMedica Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Bacterial Vaginosis
Interventions: Placebo, TOL-463; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Birmingham, Alabama • La Jolla, California • Chicago, Illinois + 1 more

Conditions: Dyspareunia
Interventions: Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride, Pelvic Rehabilitation; Drug · Procedure
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix, Intracranial Sarcoma
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 0 Minutes to 100 Years
Enrollment: 3,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2036
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions: Not listed
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more

Conditions: Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Bupropion 150 mg XL, Placebo; Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 362
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 262 more

Conditions: Pelvic Organ Prolapse, Hysterectomy, Urinary Tract Infection
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Vaginal Vault Prolapse, Post-Hysterectomy Vaginal Vault Prolapse, Prolapse, Vaginal
Interventions: Intraperitoneal Uterosacral Ligament Suspension, Extraperitoneal Uterosacral Ligament Suspension; Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bacterial Vaginosis, Urogenital Infection by Trichomonas Vaginalis
Interventions: OSOM Trichomonas Rapid Test, OSOM BVBlue Test; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 15 Years and older · Female only
Enrollment: 519 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Human Immunodeficiency Virus
Interventions: Silicone Elastomer Vaginal Ring, Female Condom; Combination Product · Device
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cervical Cancer, Vaginal Cancer
Interventions: therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Candidiasis, Vulvovaginal
Interventions: VT-1161, Fluconazole; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Lake Worth, Florida • North Miami, Florida • Brooklyn, New York + 5 more

Conditions: Bacterial Vaginosis
Interventions: LC106; Drug
Lead sponsor: Caroline Mitchell; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endometrial Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Genital Neoplasms, Female
Interventions: Psychosocial; Behavioral
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 20 Years to 75 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Columbus, Ohio

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • Brooklyn, New York

Conditions: Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness, Chronic UTI
Interventions: Hybrid Fractional Laser; Device
Lead sponsor: Sciton; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Gatos, California • Pensacola, Florida • New Orleans, Louisiana + 3 more

Conditions: Bacterial Vaginosis
Interventions: Tinidazole; Drug
Lead sponsor: Mission Pharmacal; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer
Interventions: Lorigerlimab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • New Orleans, Louisiana • Grand Rapids, Michigan + 4 more

Conditions: Sexually Transmitted Disease (STD), Gonorrhea, Chlamydia, Trichomonas Infection
Interventions: Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas; Diagnostic Test
Lead sponsor: Queen's Medical Center; Other
Eligibility: 14 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Vaginosis, Bacterial
Interventions: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Search by objective public record fields.

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing

Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy

Prospective Collection of Female and Male Specimens for PANTHER® System Testing

Tap Block vs Conventional Pain Medication for Patients Undergoing Robotic Sacrocolpopexy

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain

International PPB/DICER1 Registry

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Evaluation of the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After Hysterectomy

Intraperitoneal and Extraperitoneal Uterosacral Ligament Suspensions for Post-Hysterectomy Vaginal Vault Prolapse

A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test

A Trial to Assess the Functionality of Female Condom With a Silicone Elastomer Vaginal Ring

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

Impact of Clinician-administered Vaginal Live Biotherapeutic Product

Questionnaire Study for Gynecological Cancer Survivors

Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

Treatment of Bacterial Vaginosis With Oral Tinidazole

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision

Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers